Pyrimethamine

Generic Name
Pyrimethamine
Brand Names
Daraprim
Drug Type
Small Molecule
Chemical Formula
C12H13ClN4
CAS Number
58-14-0
Unique Ingredient Identifier
Z3614QOX8W
Background

One of the folic acid antagonists that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis.

Indication

For the treatment of toxoplasmosis and acute malaria; For the prevention of malaria in areas non-resistant to pyrimethamine

Associated Conditions
Toxoplasmosis
Associated Therapies
-
Clinical Trials
Related News

A Phase I Study of Pyrimethamine in Patients With GM2 Gangliosidosis

First Posted Date
2008-05-19
Last Posted Date
2013-02-25
Lead Sponsor
Exsar Corporation
Registration Number
NCT00679744
Locations
🇺🇸

University Hospitals of Cleveland, Cleveland, Ohio, United States

🇺🇸

New York University, School of Medicine, Department of Neurology, New York, New York, United States

🇨🇦

Division of Clinical & Metabolic Genetics, Hospital for Sick Children, Toronto, Ontario, Canada

Effect of Specific Anti-Toxoplasmatic Add-on Medication in Toxoplasma Gondii Seropositive Individuals With Schizophrenia or Major Depression

Phase 3
Completed
Conditions
Schizophrenia
Major Depression
First Posted Date
2006-03-08
Last Posted Date
2006-05-22
Lead Sponsor
Zentrum für Integrative Psychiatrie
Target Recruit Count
40
Registration Number
NCT00300404

Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome

First Posted Date
2003-07-22
Last Posted Date
2008-03-04
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
8
Registration Number
NCT00065390
Locations
🇺🇸

National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States

A Controlled Comparative Trial of Sulfamethoxazole-Trimethoprim Versus Aerosolized Pentamidine for Secondary Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients Receiving Azidothymidine (AZT)

First Posted Date
2001-08-31
Last Posted Date
2021-11-03
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
322
Registration Number
NCT00000727
Locations
🇺🇸

University of Washington AIDS CRS, Seattle, Washington, United States

🇺🇸

Bmc Actg Crs, Boston, Massachusetts, United States

🇺🇸

Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis, Indiana, United States

and more 6 locations

Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse

Not Applicable
Completed
Conditions
Toxoplasmosis, Cerebral
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
Palo Alto Medical Foundation
Registration Number
NCT00002064
Locations
🇺🇸

Palo Alto Med Foundation, Palo Alto, California, United States

A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection

Not Applicable
Completed
Conditions
Toxoplasmosis, Cerebral
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2012-10-29
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
600
Registration Number
NCT00000666
Locations
🇺🇸

AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States

🇺🇸

Community Consortium of San Francisco, San Francisco, California, United States

🇺🇸

Louisiana Comm AIDS Rsch Prog / Tulane Univ Med, New Orleans, Louisiana, United States

and more 13 locations

A Pilot Study of Oral Clindamycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS

Not Applicable
Completed
Conditions
Toxoplasmosis, Cerebral
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2012-05-18
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
30
Registration Number
NCT00000674
Locations
🇺🇸

USC CRS, Los Angeles, California, United States

🇺🇸

Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States

🇺🇸

Univ. of Miami AIDS CRS, Miami, Florida, United States

and more 10 locations

A Study of Pyrimethamine in the Treatment of Infection by a Certain Parasite in HIV-Positive Patients

Phase 1
Completed
Conditions
Toxoplasmosis, Cerebral
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2021-11-04
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
26
Registration Number
NCT00000973
Locations
🇺🇸

Unc Aids Crs, Chapel Hill, North Carolina, United States

🇺🇸

Memorial Sloan-Kettering Cancer Ctr., New York, New York, United States

Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis

Phase 2
Completed
Conditions
HIV Infections
Toxoplasmosis, Cerebral
First Posted Date
2001-08-31
Last Posted Date
2021-10-28
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
100
Registration Number
NCT00000794
Locations
🇺🇸

Northwestern University CRS, Chicago, Illinois, United States

🇺🇸

Cook County Hosp. CORE Ctr., Chicago, Illinois, United States

🇺🇸

Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States

and more 13 locations

A Study of Azithromycin Plus Pyrimethamine in the Treatment of a Brain Infection in Patients With AIDS

Phase 1
Completed
Conditions
Toxoplasmosis, Cerebral
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2008-08-26
Lead Sponsor
Pfizer
Target Recruit Count
45
Registration Number
NCT00000966
Locations
🇺🇸

Los Angeles County - USC Med Ctr, Los Angeles, California, United States

🇺🇸

Univ of Massachusetts Med Ctr, Worcester, Massachusetts, United States

🇺🇸

Univ of Miami School of Medicine, Miami, Florida, United States

and more 8 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy